You are here

Clinical Trials: Cord Blood

Conditions:   Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation;   Recurrent Lip and Oral Cavity Carcinoma;   Recurrent Malignant Endocrine Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Male Reproductive System Neoplasm;   Recurrent Malignant Mesothelioma;   Recurrent Malignant Neoplasm of Multiple Primary Sites;   Recurrent Malignant Oral Neoplasm;   Recurrent Malignant Pharyngeal Neoplasm;   Recurrent Malignant Skin Neoplasm;   Recurrent Malignant Soft Tissue Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Malignant Thyroid Gland Neoplasm;   Recurrent Malignant Urinary System Neoplasm;   Recurrent Melanoma of the Skin;   Refractory Cutaneous Melanoma;   Refractory Malignant Bone Neoplasm;   Refractory Malignant Endocrine Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm;   Refractory Malignant Male Reproductive System Neoplasm;   Refractory Malignant Mesothelioma;   Refractory Malignant Neoplasm of Multiple Primary Sites;   Refractory Malignant Oral Neoplasm;   Refractory Malignant Pharyngeal Neoplasm;   Refractory Malignant Skin Neoplasm;   Refractory Malignant Soft Tissue Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Malignant Thyroid Gland Neoplasm;   Refractory Malignant Urinary System Neoplasm
Interventions:   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cyclophosphamide;   Drug: Etoposide
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Condition:   Inherited Metabolic Disorders (IMD)
Intervention:   Drug: MGTA-456
Sponsor:   Magenta Therapeutics, Inc.
Not yet recruiting
Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytogenetic Abnormality;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Thiotepa;   Radiation: Total-Body Irradiation;   Biological: Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated
Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation
Sponsor:   Weill Medical College of Cornell University
Condition:   Severe Bronchopulmonary Dysplasia
Interventions:   Biological: PNEUMOSTEM;   Other: Placebo
Sponsor:   Medipost Co Ltd.
Not yet recruiting
Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Combination Product: Stem Cell Educator therapy
Sponsors:   Tianhe Stem Cell Biotechnologies Inc.;   Chinese PLA General Hospital
Condition:   Bronchopulmonary Dysplasia
Interventions:   Drug: transplantation of mesenchymal stem cell;   Drug: no transplantation of mesenchymal stem cell
Sponsors:   Daping Hospital and the Research Institute of Surgery of the Third Military Medical University;   Children's Hospital of Chongqing Medical University;   Chongqing Maternal and Child Health Hospital
Conditions:   Severe Aplastic Anemia;   Hypo-Plastic MDS;   Myelodysplastic Syndrome (MDS)
Intervention:   Biological: CordIn(TM)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 18, 2017
Condition:   Alzheimer's Disease
Interventions:   Biological: human umbilical cord blood derived mesenchymal stem cells;   Other: Normal saline 2mL
Sponsor:   Medipost Co Ltd.
Recruiting - verified May 2017
Condition:   Acute Graft Versus Host Disease
Intervention:   Biological: MSCTC-0010 Dose Escalation
Sponsor:   Joseph McGuirk
Not yet recruiting - verified May 2017